Year: 2022
Type: article
Abstract: The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2-4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bispecific antibodies, mitogen-activated protein kinase (MAPK) inhibitors versus immunotherapy in the adjuvant setting, whether the use of corticosteroids for the management of side effects have an impact on outcomes, the choice of programmed death (PD)-1 combination therapy with cytotoxic T-lymphocyte-associated antigen (CTLA)-4 or lymphocyte-activation gene (LAG)-3, whether radiation is needed for brain metastases, when lymphadenectomy should be integrated into the treatment plan and then the last debate, telemedicine versus face-to-face. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. Audiences voted both before and after each debate.
Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Memorial Sloan Kettering Cancer Center, The Netherlands Cancer Institute, Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, New York University, Université Paris-Saclay, Institut Gustave Roussy, The Maria Sklodowska-Curie National Research Institute of Oncology, NYU Langone Health, Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,190
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4229452018